Explanipedia

Home-based dim light melatonin onset assessment among adults with obesity: feasibility and procedural considerations Open

Francisco Romo‐Nava, Helen J. Burgess, Thomas J. Blom, Georgi P. Georgiev, Jeffrey J. Stoddard , et al. · 2025

Study Objectives Dim light melatonin onset (DLMO) is the best-established marker of central circadian phase and may contribute to unraveling the role of the circadian system in obesity. This study evaluated DLMO among individuals with obes…

Psychometric evaluation of the Symptoms of Infection with Coronavirus-19 (SIC): results from a cross-sectional study and a phase 3 clinical trial Open

Eric K. H. Chan, Valerie Williams, Carla DeMuro, Sheri Fehnel, Ashley F. Slagle , et al. · 2023

1069. Psychometric Properties of the Symptoms of Infection with Coronavirus-19: A Patient-Reported Outcome Measure for COVID-19 Signs and Symptoms Open

Eric K. H. Chan, Jeffrey J. Stoddard, Jerald Sadoff, Yan Liu, Ilse Van Dromme , et al. · 2022

Background The Symptoms of Infection with Coronavirus-19 (SIC), a patient reported outcome (PRO) measure, was developed to assess COVID-19 signs and symptoms. Qualitative and cross-sectional studies demonstrated its content validity and pr…

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial Open

Karin Hardt, An Vandebosch, Jerald Sadoff, Mathieu Le Gars, Carla Truyers , et al. · 2022

Development of a novel patient-reported outcome measure to assess signs and symptoms of COVID-19 Open

Carla DeMuro, Sheri Fehnel, Jeffrey J. Stoddard, Jerald Sadoff, Sandy Lewis , et al. · 2022

Burden of opioid use for pain management among adult herpes zoster patients in the US and the potential impact of vaccination Open

Jean‐Etienne Poirrier, Jessica K. DeMartino, Saurabh Nagar, Justin Carrico, Katherine A. Hicks , et al. · 2022

PLAIN LANGUAGE SUMMARYWhat is the context? Herpes zoster or shingles and its complications such as postherpetic neuralgia - a painful condition that affects the nerve fibers and skin - may lead to complex pain that can be addressed …

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S Open

Jerald Sadoff, Glenda Gray, An Vandebosch, Vicky Cárdenas, Georgi Shukarev , et al. · 2022

A single dose of Ad26.COV2.S provided 52.9% protection against moderate to severe-critical Covid-19. Protection varied according to variant; higher protection was observed against severe Covid-19, medical intervention, and death than again…

Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States Open

William L. Herring, Yuanhui Zhang, Vivek Shinde, Jeffrey J. Stoddard, Sandra E. Talbird , et al. · 2021

Despite variability and gaps in the epidemiology literature, this study highlights the potential value of RSV vaccination for older adults in the US. Our analysis provides contemporary estimates of the population-level RSV disease burden a…

Estimated Public Health Impact of the Recombinant Zoster Vaccine Open

Brandon J. Patterson, Philip O. Buck, Desmond Curran, Desirée Van Oorschot, Justin Carrico , et al. · 2021

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 Open

Jerald Sadoff, Glenda Gray, An Vandebosch, Vicky Cárdenas, Georgi Shukarev , et al. · 2021

A single dose of Ad26.COV2.S protected against symptomatic Covid-19 and asymptomatic SARS-CoV-2 infection and was effective against severe-critical disease, including hospitalization and death. Safety appeared to be similar to that in othe…

996. The Potential for Reducing Opioid and Analgesic Prescriptions Via Herpes Zoster Vaccination Open

Jean‐Etienne Poirrier, Justin Carrico, Jessica K. DeMartino, Katherine A. Hicks, Jeffrey J. Stoddard , et al. · 2020

Background Herpes zoster (HZ), or shingles, is a common neurocutaneous disease caused by the reactivation of latent varicella zoster virus that often includes rash and neuropathic pain that may last for months. Opioids and other analgesics…

Fighting against a protean enemy: immunosenescence, vaccines, and healthy aging Open

Giuseppe Del Giudice, Jörg J. Goronzy, Beatrix Grubeck‐Loebenstein, Paul‐Henri Lambert, Tomáš Mrkvan , et al. · 2017

The epidemiology of medically attended respiratory syncytial virus in older adults in the United States: A systematic review Open

Ann Colosia, Jin Yang, Eric Hillson, Josephine Mauskopf, Catherine Copley‐Merriman , et al. · 2017

Protection of older adults against RSV could reduce respiratory-related burden, especially as age increases and the prevalence of comorbidities (especially cardiopulmonary comorbidities) grows.

Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults Open

Louis Fries, Vivek Shinde, Jeffrey J. Stoddard, D. Nigel Thomas, Eloi Kpamegan , et al. · 2017

Oral and Long-Acting Injectable Naltrexone Open

Jeffrey J. Stoddard, Jacqueline Zummo · 2015

The recent commentary "Acamprosate, Alcoholism, and Abstinence" 1 by Barbara J. Mason provides an excellent overview of the Sunrise Study by Higuchi for the Japanese Acamprosate Study Group. 2 However, Mason incorrectly states that naltrex…

Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge Open

Steven C. Marcus, Jacqueline Zummo, Amy R. Pettit, Jeffrey J. Stoddard, Jalpa A. Doshi · 2015

This claims-based analysis of posthospitalization adherence and rehospitalization outcomes in Medicaid patients with schizophrenia adds to the growing real-world evidence base of the benefits of LAI antipsychotic medications in routine cli…

Concurrent Oral Antipsychotic Drug Use Among Schizophrenia Patients Initiated on Long-Acting Injectable Antipsychotics Post-Hospital Discharge Open

Jalpa A. Doshi, Amy R. Pettit, Jeffrey J. Stoddard, Jacqueline Zummo, Steven C. Marcus · 2015

Pharmacological treatment is central to effective management of schizophrenia. Prescribing clinicians have an increasing array of options from which to choose, and oral antipsychotic polypharmacy is common in routine clinical practice. Pra…

Jeffrey J. Stoddard YOU? Author Swipe